Andrew Hall

CEO and board member of Consano Bio. He previously led IMV Inc., a clinical-stage biopharmaceutical company in oncology that was acquired in 2023. Before IMV, Andrew spent 7 years at Celgene, where he led corporate development and pipeline strategy for immunology, as well as business development and strategic alliances, working on deals from discovery to commercialization.

Andrew also spent more than 15 years at Merck, BMS, and Schering Plough in leadership roles across Asia Pacific, Europe and the US.